: 12/02/2021 Subject
: phone call with EFPIA Participants
: DG SANTE: Sandra Gallina (SG), Pierre Delsaux (PD),
SG presented the origin, rationale and functioning of the export-licensing
scheme, aimed to ensure transparency of flows of vaccines.
presented EFPIA’s perspective. EFPIA supports transparency, but is
concerned by potential delays caused by the export authorisation process.
An EFPIA WG will discuss possibilities to speed up the export authorisation
Structured approach to manufacturing / IP
EFPIA will announce initiatives on IP, to avoid compulsory licensing. In IT,
companies will announce that they are available to produce vaccines. Other MS
EFPIA would welcome a structured approach to vaccine production capacity.
Commissioner Breton is looking into possibilities of increasing production
PD informed about an upcoming Communication on bio preparedness, with
emphasis on variants and agile production capacity.
EFPIA to identify date with PD for ‘pipeline review’ event. EFPIA calls for a forum
to discuss concrete proposals under the strategy.
SG indicated the importance for pharma to assume its societal responsibility,
help address the problems of access to medicines in the smaller markets (notably
post BREXIT) and actively contribute to the pharmaceutical strategy. Important
to ‘fix’ the system together.
EFPIA is working on measures to improve transparency and access to medicines.
EFPIA is preparing feedback on the inception impact assessment to share with
the Commission next week.